ERBB2 and breast cancer: The result of phase 3 clinical trial (DESTINY Breast-04, DB-04) of T-Dxd in previously heavily-treated HER2-low advanced BC was published in June 2022 and it showed T-Dxd significantly improved survival in patients with HER2-low advanced BC, compared to chemotherapy of physician choice [12].